Drug developers aren’t expected to come back to the US equity markets in full force until next year — lagging other ...

Launched on 06/23/2005, the Invesco Biotechnology & Genome ETF (PBE) is a passively managed exchange traded fund designed to provide a broad exposure to the Healthcare - Biotech segment of the equity ...

Diversification, especially including international holdings, is crucial for biotech investors to optimize portfolio performance amid market shifts. Despite broader industry weakness, quality ...

The beauty industry is undergoing a significant transformation, driven by scientific advances, evolving consumer expectations ...

An announcement from Moleculin Biotech ( ($MBRX) ) is now available. On May 23, 2025, Moleculin Biotech received a notification from Nasdaq ...

ZURICH, SWITZERLAND, May 29, 2025 -- VERAXA Biotech AG (“VERAXA”), an emerging leader in designing novel cancer therapies and proposed de-SPAC acquisition target of Voyager Acquisition Corp.

Performance data quoted represents past performance, which does not guarantee future results. Current performance may be lower or higher than the figures shown. Principal value and investment ...

Launched on 06/23/2005, the Invesco Biotechnology & Genome ETF (PBE) is a smart beta exchange traded fund offering broad exposure to the Health Care ETFs category of the market. What Are Smart Beta ...

After two decades in military research and biotech entrepreneurship, Robert Kenefick has circled back to where his scientific journey began—academia. Kenefick, who was named chair of the Biomedical ...

Despite challenges, thematic and sector ETFs can have a meaningful role within an intelligently constructed portfolio.

VERAXA Biotech AG (“VERAXA”), an emerging leader in designing ... Islands exempted company and special purpose acquisition company targeting the healthcare sector (NASDAQ: VACH, "Voyager"). Upon ...

Victor Li, Chairman of CKLIFE SCIENCES (00775.HK), was asked about his views on the company's prospects after the ...